Cadrenal Therapeutics (CVKD.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Nov11

Noble Financial Maintains Buy Rating on Cadrenal Therapeutics with a Target Price of $45

15:04

Cadrenal Therapeutics released FY2025 Q3 earnings on November 10 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.3139 (forecast USD -1.445)

04:00

Cadrenal Therapeutics released FY2025 9 Months Earnings on November 10 (EST), Actual Revenue: USD 0, Actual EPS: USD -5.2686

04:00

Aug12

Cadrenal Therapeutics released FY2025 Q2 earnings on August 11 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -1.8694 (forecast USD -1.5966)

03:00

Cadrenal Therapeutics released FY2025 Semi-Annual earnings on August 11, 2025 (EST) with actual revenue USD 0 and EPS USD -3.9473

03:00

Jun12

Cadrenal Therapeutics Inc. Announces Tecarfarin Study Results

12:02